Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Tulln An Der Donau – page 2

881 clinical trials in Tulln An Der Donau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tulln An Der Donau at a glance
881
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

881 trials in Tulln An Der Donau

Open in trial search

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Tulln An Der Donau

What the registry says about research in the country

01 Neurological Disorders

Research focusing on Multiple System Atrophy and its associated conditions, particularly investigating new therapeutic approaches for managing neurogenic orthostatic hypotension. Studies aim to evaluate novel treatments for improving patient symptoms and quality of life.

  • Orthostatic Hypotension Management
  • Autonomic Nervous System Disorders
  • Symptomatic Treatment Evaluation

Current trials are examining long-term effectiveness and durability of new therapeutic interventions.

02 Neuropathic Pain Studies

Comprehensive research into various forms of chronic neuropathic pain, including diabetic polyneuropathy and post-operative peripheral neuropathy. Studies are evaluating new therapeutic options for patients with treatment-resistant conditions.

  • Diabetic Polyneuropathy
  • Traumatic Neuropathy
  • Central Neuropathy

Investigations focus on add-on treatments to enhance current pain management protocols.

03 Chronic Pain Management

Innovative research targeting chronic back pain and various pain conditions, evaluating new therapeutic approaches for improved patient outcomes. Studies are designed to assess both efficacy and tolerability of novel treatment options.

  • Back Pain Treatment
  • Pain Management Protocols
  • Treatment Tolerability Assessment

Current research emphasizes developing comprehensive pain management solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.